The Phase II Study of Docetaxel plus Nedaplatin as Adjuvant Chemotherapy in Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000004634
- Lead Sponsor
- Shiga University of Medical Science
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1. Allergy against polysorbert 80 or platinum-containing drugs 2. Severe complications (i.e. ischemic heart diseases required treatment, arrhythmia, myocardial infarction within 6 months, liver cirrhosis, uncontrolled diabetes, hemorrhagic tendency) 3. Active infections 4. Massive pleural or pericardial effusion 5. Active simultaneous cancer 6. Active interstitial pneumonitis or its past history 6. Peripheral nerve disorders 7. Pregnant or lactating women 8. Other conditions not suitable for this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method